Your fact-checks will appear here
The approval of Lecanemab (Leqembi) for Alzheimer's treatment and its conversion to traditional approval.
‑approved anti‑amyloid therapies for early symptomatic Alzheimer’s disease require evidence of brain amyloid pathology before initiation, and clinicians most commonly rely on amyloid PET imaging or ce...
Two categories of reliable, FDA‑approved treatments exist for Alzheimer’s disease today: longstanding symptomatic therapies that can modestly improve cognition or behavior, and a new class of anti‑amy...
FDA approval of a dementia treatment rests on a sequence of regulatory steps: preclinical research, phased clinical trials demonstrating safety and efficacy, review under standard or expedited pathway...
The evaluates drugs through either traditional (full) approval or the Accelerated Approval pathway; the latter allows earlier market access when a drug affects a surrogate endpoint “reasonably likely ...
Two classes of treatments exist today: longstanding symptomatic drugs that modestly delay decline (cholinesterase inhibitors and memantine) and a new wave of anti‑amyloid immunotherapies that reduce b...
Three monoclonal antibody treatments that target amyloid-beta have been approved by U.S. regulators in recent years: aducanumab (Aduhelm) in 2021, lecanemab (Leqembi) in 2023 with updated maintenance ...
As of 2025 the FDA’s approved arsenal for Alzheimer’s disease includes new anti-amyloid monoclonal antibodies for early-stage illness, longstanding symptom‑relief drugs, and a few recent approvals for...
Dementia "medicine" today divides into long-standing symptom-managing drugs and a new generation of disease-modifying biologics that slow—but do not cure—Alzheimer’s disease; clinicians stress early d...
The FDA’s accelerated approval pathway lets Alzheimer’s drugs reach patients earlier by allowing approval on surrogate endpoints “reasonably likely” to predict benefit, with mandatory post‑marketing (...
The FDA now recognizes two classes of treatments for Alzheimer’s: disease‑modifying, amyloid‑targeting monoclonal antibodies that can modestly slow clinical decline in early disease, and older symptom...